Making sense of triple inhaled therapy for COPD

New England Journal of Medicine

Volumn 378, Issue 18, 2018, Pages 1723-1724

  Suissa, Samy ^a   Drazen, Jeffrey M ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE FUROATE; GLUCOCORTICOID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; UMECLIDINIUM; VILANTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DRUG EFFICACY; EDITORIAL; EOSINOPHIL; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MEDICAL HISTORY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85046280496     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1716802     Document Type: Editorial

References (10)

1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD Executive Summary. Eur Respir J 2017;49(3):1700214.
2. Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J 2015;45:525-37.
3. Rodriguez-Roisin R, Rabe KF, Vestbo J, Vogelmeier C, Agustí A. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th anniversary: a brief history of time. Eur Respir J 2017;50:50.
4. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. DOI: 10.1056/NEJMoa1713901.
5. Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? Lancet Respir Med 2017;5:747-59.
6. Suissa S, Ernst P. Precision medicine urgency: the case of inhaled corticosteroids in COPD. Chest 2017;152:227-31.
7. Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008;31: 927-33.
8. Vestbo J, Anderson JA, Calverley PM, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J 2011;5:44-9.
9. Suissa S. Will SUMMIT reach the peak in COPD? Thorax 2014;69:405-7.
10. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016;374:2222-34.